美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Neuroscience and Healthcare ETF

36.55

+0.52921.47%

盤後：36.560.0073+0.02%16:10 EDT

成交量：6,618

成交額：24.29萬

市值：731.05萬

市盈率：- -

高：36.78

開：36.37

低：36.37

收：36.02

52周最高：43.01

52周最低：25.42

股本：20.00萬

流通股本：20.00萬

量比：4.39

換手率：3.31%

股息：0.32

股息率：0.88%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Scholar Rock Holding Corporation 已全面就緒，只待FDA批准即刻啓動Apitegromab美國上市

Scholar Rock宣佈FDA受理Apitegromab治療脊髓性肌萎縮症（SMA）的生物製品許可申請（BLA），並推進第二家灌裝-封裝工廠建設；預計2026年9月30日前作出審批決定

Scholar Rock Holding Corp 與歐洲藥品管理局溝通，計劃將第二家灌裝-封裝設施納入Apitegromab上市申請

「蒸餾」你的大腦，腦機這門生意竟然價值上億

港股異動 | 英硅智能(03696)升逾9% ISM8969/HT-001已獲NMPA臨床試驗批件擬用於帕金森病治療

Praxis Precision Medicines發布公司動態及2026年第二季度財務報告

Scholar Rock第二季度淨虧損收窄；FDA審查取得進展

北京海淀加速打造腦機接口新高地核心企業佔全國近60%

北京海淀加速打造腦機接口新高地核心企業佔全國近60%

北京海淀加速打造腦機接口新高地核心企業佔全國近60%

蚌埠市腦機接口科技發展公司登記成立

Dianthus Therapeutics 披露截至2026年6月30日現金儲備達12億美元，預期運營資金可持續至2030年

Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 與 Baff/April 通路，佈局自身免疫疾病領域

Dianthus Therapeutics：DNTH312在非人靈長類模型中展現與Povetacicept相當的免疫球蛋白降低效果

宇樹科技早期投資人，盯上了成都腦機接口公司

每日经济新闻

多地密集下注腦機接口產業

3.3億！中國腦機接口最大天使輪融資完成

腦機接口板塊短線拉升，創新醫療漲停

規範產業發展提升生活品質

中国质量报

女子因車禍導致雙手及下肢癱瘓，安徽為其開出全省首張腦機接口「處方」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBRN/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":36.5527,"timestamp":1789675200000,"preClose":36.0235,"halted":0,"volume":6618,"hourTrading":{"tag":"盘后","latestPrice":36.56,"preClose":36.5527,"latestTime":"16:10 EDT","volume":6,"amount":219.3308,"timestamp":1789675804167,"change":0.0073,"changeRate":0.0002,"amplitude":0},"delay":0,"changeRate":0.014690410426527212,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"已收盤","change":0.5292,"latestTime":"09-17 16:00:00 EDT","open":36.3701,"high":36.78,"low":36.3701,"amount":242899,"amplitude":0.011379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":36.0235,"sharesOutstanding":150000,"nav":36.037194,"aum":7207438.8,"dividendRate":0.008771,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":36.56,"preClose":36.5527,"latestTime":"16:10 EDT","volume":6,"amount":219.3308,"timestamp":1789675804167,"change":0.0073,"changeRate":0.0002,"amplitude":0},"volumeRatio":4.394423,"impliedVol":0.0187,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.394423,"shares":200000,"dividePrice":0.3206,"high":36.78,"amplitude":0.011379,"preClose":36.0235,"low":36.3701,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":36.5527,"eps":0,"divideRate":0.008771,"volume":6618,"delay":0,"ttmEps":0,"open":36.3701,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":37.33,"twentyDayClose":40.6657,"sixtyDayClose":36.8908},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1109042786","title":"Scholar Rock Holding Corporation 已全面就緒，只待FDA批准即刻啓動Apitegromab美國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1109042786","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109042786?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134077,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation 已做好充分准备。一旦获得美国食品药品监督管理局（FDA）的批准，他们将立即启动Apitegromab在美国市场的上市。该公司正蓄势待发，静候监管绿灯的亮起，以便迅速将这款药物推向市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180768754","title":"Scholar Rock宣佈FDA受理Apitegromab治療脊髓性肌萎縮症（SMA）的生物製品許可申請（BLA），並推進第二家灌裝-封裝工廠建設；預計2026年9月30日前作出審批決定","url":"https://stock-news.laohu8.com/highlight/detail?id=1180768754","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180768754?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134073,"startTime":"0","endTime":"0","summary":"Scholar Rock公司今日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Apitegromab用于治疗脊髓性肌萎缩症（SMA）的生物制品许可申请（BLA）。与此同时，该公司正积极推进第二家灌装-封装工厂的建设。市场预期，FDA将在2026年9月30日的行动日期前作出最终审批决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119566389","title":"Scholar Rock Holding Corp 與歐洲藥品管理局溝通，計劃將第二家灌裝-封裝設施納入Apitegromab上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1119566389","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119566389?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134070,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corp 正积极与欧洲药品管理局（EMA）展开沟通。该公司旨在将第二处灌装-封装生产设施，纳入其实验性药物Apitegromab的上市许可申请（MAA）中。这一举措，凸显了其对于扩大生产能力的战略布局。通过此举，公司期望能优化供应链韧性，并确保未来药物获批后的稳定供应。此举不仅关乎生产规模，更体现了对监管流程的深度参与与前瞻性规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SRRK","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612550","title":"「蒸餾」你的大腦，腦機這門生意竟然價值上億","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612550","media":"虎嗅网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612550?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 15:22","pubTimestamp":1786087345,"startTime":"0","endTime":"0","summary":"2026年上半年，国内脑机接口领域发生了47起融资事件，披露总额超过53亿元，占这个赛道历史融资总额的近六成，单半年规模已远超2025年全年。据李昕介绍，华超是国内少数将超声作为核心技术路线、同时自研读取和干预闭环的非侵入式脑机接口公司。对一家成立刚满一年的脑机接口公司来说，这不寻常。这个团队负责建立大脑模型、识别调控焦点、理解干预效果，同时从脑机接口获取新的模式反哺模型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vONreNLVH1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["AIPO","CHAT","MNTL","QTOC","VTHR","IBRN","ARTY","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691079","title":"港股異動 | 英硅智能(03696)升逾9% ISM8969/HT-001已獲NMPA臨床試驗批件 擬用於帕金森病治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691079","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657691079?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:04","pubTimestamp":1786082650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰生物共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局临床试验批件，拟用于帕金森病治疗。此前，英硅智能于2026年1月宣布与复星健康资本旗下深圳鹏复基金与复星医药的被投企业衡泰生物达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1612","HT","BMED","BK1141","IBBJ","IBBQ","IBRN","VXUS","01611","BK4218","03696","BK4181","PSYK","BK4585","KCAI","BK4588","MDTX","BK1167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109275243","title":"Praxis Precision Medicines發布公司動態及2026年第二季度財務報告","url":"https://stock-news.laohu8.com/highlight/detail?id=1109275243","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109275243?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 20:02","pubTimestamp":1786017736,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. 近日公布了公司最新进展情况，并同时披露了2026年第二季度的财务业绩。此次更新，不仅涵盖了公司运营层面的关键动态，也清晰展示了其截至该季度的财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","PRAX","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635286","title":"Scholar Rock第二季度淨虧損收窄；FDA審查取得進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635286","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635286?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 19:46","pubTimestamp":1786016772,"startTime":"0","endTime":"0","summary":"BUZZ-Scholar Rock第二季度净亏损收窄；FDA审查取得进展8月6日-** Scholar Rock（SRRK.O）股价在盘前交易中上涨9.69%，至52.51美元** 第二季度每股净亏损为0.84美元，而去年同期为每股0.98美元** 公司表示，其脊髓性肌萎缩症药物的申请正在接受FDA审查，进展持续推进，目前有两家灌装和包装工厂，这意味着有两条独立的审批路径，预计最迟将于9月30日作","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4T443175:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","IBRN","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685839","title":"北京海淀加速打造腦機接口新高地 核心企業佔全國近60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685839","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657685839?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 15:53","pubTimestamp":1786002786,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据央视新闻报道，从中关村科学城管委会获悉，北京市海淀区已集聚超30家脑机接口核心企业，占全国近60%，已形成“基础研究-技术攻关-产品研发-临床应用”的全链条创新生态，一个脑机接口新高地正在崛起。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/MzNhMjUxNDI3Yzg1Yjg1NGVkN2ZhNDc2YWI2MTA4NTA5OTA5OTQ4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/MzNhMjUxNDI3Yzg1Yjg1NGVkN2ZhNDc2YWI2MTA4NTA5OTA5OTQ4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683924","title":"北京海淀加速打造腦機接口新高地 核心企業佔全國近60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683924","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657683924?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 15:40","pubTimestamp":1786002058,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657245683","title":"北京海淀加速打造腦機接口新高地 核心企業佔全國近60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657245683","media":"央视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657245683?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 15:40","pubTimestamp":1786002000,"startTime":"0","endTime":"0","summary":"近日记者从中关村科学城管委会获悉，北京市海淀区已集聚超30家脑机接口核心企业，占全国近60%，已形成“基础研究-技术攻关-产品研发-临床应用”的全链条创新生态，一个脑机接口新高地正在崛起。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-06/doc-inimkfvf4674782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657504937","title":"蚌埠市腦機接口科技發展公司登記成立","url":"https://stock-news.laohu8.com/highlight/detail?id=2657504937","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657504937?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 13:42","pubTimestamp":1785994970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122665642","title":"Dianthus Therapeutics 披露截至2026年6月30日現金儲備達12億美元，預期運營資金可持續至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1122665642","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122665642?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:37","pubTimestamp":1785875839,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 最新披露，截至2026年6月30日，公司持有现金储备高达12亿美元。基于当前资金状况，管理层预期这一现金跑道将支持公司运营直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186641577","title":"Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 與 Baff/April 通路，佈局自身免疫疾病領域","url":"https://stock-news.laohu8.com/highlight/detail?id=1186641577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186641577?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 19:11","pubTimestamp":1785841890,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 公司正着力推进其核心候选药物 Dnth312。该药物旨在通过抑制 Ac1s 以及 Baff/April 这两条关键信号通路，为自身免疫性疾病患者提供全新的治疗策略。此举展现了公司在免疫调节领域的前沿探索与雄心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111288447","title":"Dianthus Therapeutics：DNTH312在非人靈長類模型中展現與Povetacicept相當的免疫球蛋白降低效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1111288447","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111288447?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 19:11","pubTimestamp":1785841869,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，其候选药物 DNTH312 在非人灵长类动物（NHPs）研究中，显示出与 Povetacicept 相似的免疫球蛋白降低能力。这一发现表明，DNTH312 在调节免疫反应方面具有潜在的治疗价值。该研究的详细数据尚未完全公布，但初步结果已为后续的临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656534469","title":"宇樹科技早期投資人，盯上了成都腦機接口公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2656534469","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656534469?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 18:02","pubTimestamp":1785837720,"startTime":"0","endTime":"0","summary":"2026年上半年，国内脑机接口领域共发生47起融资事件，披露总金额超53.8亿元，占历史累计融资额近六成。赛道加速，已成共识。“OPC更像外界对瓦博科技早期高效率状态的一个标签，而不是公司的终局组织形态。”瓦博科技的战略定位，很快在市场上得到了验证。四川率先出台了全国首个省级脑机接口医疗服务分类定价标准，张星智认为这是一个重要的制度信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-08-04/doc-inimcxxp2096254.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-04/doc-inimcxxp2096254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","IBRN","688836"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531485","title":"多地密集下注腦機接口產業","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656531485?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:50","pubTimestamp":1785837026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656534020","title":"3.3億！中國腦機接口最大天使輪融資完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2656534020","media":"智东西","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656534020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 12:59","pubTimestamp":1785819598,"startTime":"0","endTime":"0","summary":"智东西作者 | 杨京丽编辑 | 李水青智东西8月4日报道，昨日，上海脑机接口企业主动科技宣布完成3.3亿元天使轮融资，创下中国脑机接口领域最大天使轮融资纪录。主动科技CEO吴国佳称，目前“天枢”产品即将以1024通道系统启动临床试验，公司有望成为国内首个开展1024通道侵入式脑机接口临床试验的企业。结语：脑机接口竞争迈向临床转化成立仅半年便获得3.3亿元天使轮融资，主动科技由此获得了扩建研发生产体系、推进临床试验的重要资金支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vJr3zYefp1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656586561","title":"腦機接口板塊短線拉升，創新醫療漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2656586561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656586561?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:49","pubTimestamp":1785808176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588547","title":"規範產業發展 提升生活品質","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588547","media":"中国质量报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588547?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 07:39","pubTimestamp":1785800340,"startTime":"0","endTime":"0","summary":"这两项标准的实施，有利于提升家用太阳能热水系统的产品质量和能源利用效率，促进市场良性竞争，为百姓提供科学消费指导。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-04/doc-inimcatr5756547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","BK4020","ARVR","IBRN","MAKX","GNSS","IVRS","RAYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656015347","title":"女子因車禍導致雙手及下肢癱瘓，安徽為其開出全省首張腦機接口「處方」","url":"https://stock-news.laohu8.com/highlight/detail?id=2656015347","media":"合肥日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656015347?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 12:19","pubTimestamp":1785730786,"startTime":"0","endTime":"0","summary":"王女士曾是一名设计师，一年前因车祸造成颈部脊髓损伤，导致双手及下肢瘫痪。本次手术助手、副主任医师王毅表示，脑机接口技术为这类患者带来了突破性治疗选择。据悉，王女士是全国第三例接受该脑机接口产品植入手术的患者，安徽医科大学第一附属医院是全国第二家正式开展脑机接口手术临床应用的医院。根据术中测试结果，王女士大脑运动信号稳定，质量良好，目前各项生命体征平稳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vHnsWiy9I3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}